Early snapshot of Adverum's eye gene therapy sparks concern about vision loss

Early snapshot of Adverum's eye gene therapy sparks concern about vision loss

Source: 
Endpoints
snippet: 

An early-stage update on Adverum Biotechnologies’ intravitreal gene therapy has triggered investor concern, after patients with wet age-related macular degeneration (AMD) saw their vision deteriorate, despite signs that the treatment is improving retinal anatomy.